Literature DB >> 11822882

Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.

Marcia N Gordon1, Leigh A Holcomb, Paul T Jantzen, Giovanni DiCarlo, Donna Wilcock, Kristal W Boyett, Karen Connor, Jason Melachrino, James P O'Callaghan, Dave Morgan.   

Abstract

Doubly transgenic mice expressing both a mutated amyloid precursor protein and a mutated presenilin-1 protein accumulate A(beta) deposits as they age. The early A(beta) deposits were found to be primarily composed of fibrillar A(beta) and resembled compact amyloid plaques. As the mice aged, nonfibrillar A(beta) deposits increased in number and spread to regions not typically associated with amyloid plaques in Alzheimer's disease. The fibrillar, amyloid-containing deposits remained restricted to cortical and hippocampal structures and did not increase substantially beyond the 12-month time point. Even at early time points, the fibrillar deposits were associated with dystrophic neurites and activated astrocytes expressing elevated levels of glial fibrillary acidic protein. Microglia similarly demonstrated increased staining for complement receptor-3 in the vicinity of A(beta) deposits at early time points. However, when MHC-II staining was used to assess the degree of microglial activation, full activation was not detected until mice were 12 months or older. Overall, the regional pattern of A(beta) staining resembles that found in Alzheimer disease; however, a progression from diffuse A(beta) to more compact amyloid deposits is not observed in the mouse model. It is noted that the activation of microglia at 12 months is coincident with the apparent stabilization of fibrillar A(beta) deposits, raising the possibility that activated microglia might clear fibrillar A(beta) deposits at a rate similar to their rate of formation, thereby establishing a relatively steady-state level of amyloid-containing deposits. ©2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11822882     DOI: 10.1006/exnr.2001.7754

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  99 in total

1.  Transcriptional analysis in the brain: trophin-induced hippocampal synaptic plasticity.

Authors:  Janet Alder; Smita Thakker-Varia; Ira B Black
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging.

Authors:  Mei-Ping Kung; Zhi-Ping Zhuang; Cathy Hou; Hank F Kung
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 3.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

4.  Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's.

Authors:  Ivan A Borbon; Robert P Erickson
Journal:  J Appl Genet       Date:  2010-12-18       Impact factor: 3.240

5.  Amyloid precursor protein in pancreatic islets.

Authors:  Joshua A Kulas; Kendra L Puig; Colin K Combs
Journal:  J Endocrinol       Date:  2017-07-14       Impact factor: 4.286

6.  Aging analysis reveals slowed tau turnover and enhanced stress response in a mouse model of tauopathy.

Authors:  Chad Dickey; Clara Kraft; Umesh Jinwal; John Koren; Amelia Johnson; Laura Anderson; Lori Lebson; Daniel Lee; Dennis Dickson; Rohan de Silva; Lester I Binder; David Morgan; Jada Lewis
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

Review 7.  Learning and memory deficits in APP transgenic mouse models of amyloid deposition.

Authors:  Dave Morgan
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

8.  Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.

Authors:  Niki C Carty; Kevin Nash; Daniel Lee; Mary Mercer; Paul E Gottschall; Craig Meyers; Nicholas Muzyczka; Marcia N Gordon; Dave Morgan
Journal:  Mol Ther       Date:  2008-07-29       Impact factor: 11.454

Review 9.  What can rodent models tell us about cognitive decline in Alzheimer's disease?

Authors:  Sabrina Davis; Serge Laroche
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

10.  Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

Authors:  Donna M Wilcock; Amyn Rojiani; Arnon Rosenthal; Gil Levkowitz; Sangeetha Subbarao; Jennifer Alamed; David Wilson; Nedda Wilson; Melissa J Freeman; Marcia N Gordon; Dave Morgan
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.